News

Discover groundbreaking insights on SGLT2 inhibitors and their impact on kidney health, cardiovascular outcomes, and patient care at ASN Kidney Week.

New research shows nearly all adults with hypertensive chronic kidney disease benefit from a <120 mm Hg target.

Renata Block spoke at the 2025 SDPA Fall Conference about her session on the use of artificial intelligence tools in clinical practice.

At ACAAI 2025, Shaker dispels epinephrine myths, emphasizing that it is safe, effective, and underused in anaphylaxis care.

Data presented at NASPGHAN 2025 revealed odevixibat demonstrated sustained improvements in sleep and caregiver-reported QOL in patients with Alagille syndrome through 96 weeks.

SGLT2 inhibitors show significant kidney protection for chronic kidney disease regardless of diabetes status or albumin levels.

In the phase 2b VANTAGE trial, volixibat shows meaningful gains in fatigue, sleep, and itch relief in PBC patients.

At ACAAI 2025, Shaker highlighted evolving therapies and real-world barriers that continue to limit optimal anaphylaxis management.

The SDPA president, Sarah Vicari, spoke at the 2025 SDPA Fall Conference about the conference and its significance.

The new guidance seeks to aid patient selection, comorbidity management, and monitoring the safety and effectiveness of semaglutide for MASH.

At ACAAI 2025, Durban breaks down natural allergy treatments and separates myths from evidence.

Shroff emphasizes the need to address more than just liver health in patients with alcohol-associated liver disease and reviews trends in AUD pharmacotherapy prescriptions.

Cheung explores the effect of sparsentan on urinary biomarkers in treatment-naive patients with IgA nephropathy.

Long-term analysis of the PEDFIC studies presented at NASPGHAN 2025 demonstrated sustained reductions in bile acids and pruritus with odevixibat in FIC1 deficiency.

Patients with alcohol-associated liver disease face greater stigma than other liver disease etiologies.

Findings support a sex-specific approach to MetALD and ALD definitions and the need to incorporate binge drinking frequency into clinical risk stratification.

Ahead of ACAAI 2025, HCPLive spoke with Chovatiya on challenges in translating these promising immunologic targets into real-world clinical practice.

At ACAAI 2025, HCPLive spoke with Chovatiya on the OX40/OX40L pathway and what makes it an attractive therapeutic target over other established pathways.

Khush discusses the promising results of the recent SHORE study, highlighting the new biomarker’s capacity for reducing surgical procedures.

Tegoprubart shows promise as a safer alternative to tacrolimus in kidney transplants, enhancing graft function with fewer side effects.

Julie Khlevner, MD, AGAF, highlights that FDA approval of linaclotide provides the first pharmacologic therapy for pediatric IBS-C.

This segment of Goff’s SDPA Fall 2025 interview features a discussion of dietary changes and sunscreen use as a means to improve skin health.

In this interview at SDPA Fall 2025, Goff highlights several takeaways from her session on lifestyle and diet choices among patients in the dermatology space.

Thomas Wallach, MD, discusses phase 3 safety data of tenapanor in pediatric patients with IBS-C, presented at the 2025 NASPGHAN Annual Meeting.

Jonathan Barratt, MBChB, PhD, discusses 36-week atacicept data from ASN Kidney Week 2025.

In a session presented at the 2025 SDPA Fall Conference, a review was given of common genetic syndromes with cutaneous manifestations.

New findings reveal sparsentan significantly reduces proteinuria in FSGS patients, offering hope for improved kidney health and lower failure risk.